Last updated: July 31, 2026

Application No. 18/030,222

Mutant KRAS-Targeting Peptide and Use Thereof

Non-Final OA

Filed

Apr 04, 2023

Priority

Oct 08, 2020 — RE 10-2020-0130300 +1 more

Examiner

DEVI, SARVAMANGALA

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Gjmedi Inc.

OA Round

1 (Non-Final)

Interview Optional

— +55.0% interview lift. Examiner has a relatively high allowance rate (66%); +55.0% interview lift. A written response may suffice.

Based on 869 resolved cases, 2023–2026

Examiner Intelligence

DEVI, SARVAMANGALA View full profile →

Grants 66% — above average

Career Allowance Rate

569 granted / 869 resolved

+5.5% vs TC avg

Strong +55% interview lift

Without

With

+55.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

46 currently pending

Career history

927

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

28.3%

-11.7% vs TC avg

§102

24.9%

-15.1% vs TC avg

§112

25.4%

-14.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 869 resolved cases

Prosecution Timeline

Apr 04, 2023

Application Filed

Dec 23, 2025

Non-Final Rejection (signed)

Feb 02, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/530,348

Patent 12691167

PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE

2y 7m to grant Granted Jul 28, 2026

17/757,972

Patent 12667611

NEW USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A RESPIRATORY SYNCITIAL VIRUS PROTEIN AGAINST hMPV

4y 0m to grant Granted Jun 30, 2026

18/425,772

Patent 12661411

MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE

2y 4m to grant Granted Jun 23, 2026

18/570,332

Patent 12636322

BACTERIAL STRAIN WITH HIGH CELLULOLYTIC ACTIVITY

2y 5m to grant Granted May 26, 2026

18/768,336

Patent 12637495

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

1y 10m to grant Granted May 26, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

66%

Grant Probability

99%

With Interview (+55.0%)

3y 4m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 869 resolved cases by this examiner. Grant probability derived from career allowance rate.